Integrated treatment for alcohol use and alcohol-associated liver disease
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) – Mayo Clinic
Combining liver and addiction treatments to help people with severe alcohol-related liver disease stop drinking and improve their health.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11195174 on NIH RePORTER |
What this research studies
You would receive coordinated care from liver specialists and addiction clinicians working together to prevent relapse and treat liver injury. The program may offer behavioral therapy such as motivational interviewing, FDA-approved medications for alcohol use disorder like acamprosate where safe, and testing of new drugs (for example IL-22) for severe alcohol-associated hepatitis. Some parts involve clinical trials that follow hospitalized patients with severe alcohol-associated hepatitis to track survival, liver tests, and drinking outcomes. Participation could include clinic visits, counseling sessions, medication, and blood tests over weeks to months.
Who could benefit from this research
Good fit: Adults with alcohol-associated liver disease—especially those hospitalized with severe alcohol-associated hepatitis who are willing to engage with both liver and addiction care—are the most likely candidates.
Not a fit: People without alcohol-related liver disease, those already stably abstinent, or those with medical contraindications to the trial therapies may not benefit from participation.
Why it matters
Potential benefit: If successful, this approach could reduce return-to-drinking, improve short-term survival in severe alcohol-associated hepatitis, and improve overall liver-related outcomes.
How similar studies have performed: A prior trial (AlcHepNet) reported unexpectedly high 90-day survival with prednisone that needs confirmation, acamprosate is used for alcohol use disorder but has limited data in severe ALD, and IL-22 is a novel experimental therapy.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Shah, Vijay H. — Mayo Clinic Rochester
- Study coordinator: Shah, Vijay H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.